The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Monogenetic Disease Therapy Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The monogenetic disease therapy market has demonstrated strong expansion in recent years. It is anticipated to grow from $28.3 billion in 2025 to $31.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. This historical development can be attributed to advancements in human genome research, initial gene therapy trials, an increase in rare disease diagnosis, incentives for orphan drugs, and improvements in viral vectors.

The monogenetic disease therapy market is projected to experience substantial growth in the upcoming years. It will grow to $45.58 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. This anticipated expansion over the forecast period is driven by factors such as advancements in gene editing platforms, an expanding pipeline for rare diseases, increased genetic screening rates, greater funding for personalized therapies, and broader regulatory approvals. Significant trends during this period are expected to include single gene targeted therapies, gene replacement treatment programs, RNA-based genetic treatments, rare disease gene correction, and precision genetic drug design.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33229&type=smp

Which Drivers Are Advancing The Monogenetic Disease Therapy Market Growth?

The expanding acceptance of precision and personalized medicine is anticipated to fuel the progression of the monogenetic disease therapy market in the coming years. This medical strategy involves customizing disease prevention, diagnosis, and treatment according to an individual’s unique genetic, molecular, or lifestyle characteristics, with the goal of maximizing therapeutic efficacy and minimizing adverse effects. The increasing prominence of precision and personalized medicine arises from healthcare providers and patients seeking bespoke treatments that enhance therapeutic efficacy, reduce adverse reactions, and address individual genetic, molecular, or lifestyle attributes. Monogenetic disease therapy aligns with precision and personalized medicine by directly targeting a patient’s specific genetic mutation, thereby enabling highly customized and effective interventions. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, which is an increase from six in 2022. Thus, the growing adoption of precision and personalized medicine is propelling the development of the monogenetic disease therapy market.

How Is Segment Classification Applied In The Monogenetic Disease Therapy Market?

The monogenetic disease therapy market covered in this report is segmented –

1) By Therapy Type: Pharmacological; Surgical; Blood Transfusion; Gene Therapies; Other Therapy Types

2) By Inheritance Pattern: Autosomal; Chromosomal

3) By Application: Cystic Fibrosis; Sickle Cell Anemia; Phenylketonuria; Other Applications

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-Users: Clinics; Hospitals; Diagnostic Centres; Home Healthcare; Other End-Users

Subsegments:

1) By Pharmacological: Small Molecule Drugs; Enzyme Replacement Therapies; Protein Replacement Therapies; Immunomodulatory Drugs; Targeted Molecular Therapies

2) By Surgical: Organ Transplant Procedures; Tissue Repair Surgeries; Gene Editing Assisted Surgeries; Minimally Invasive Surgeries; Corrective Surgical Interventions

3) By Blood Transfusion: Red Blood Cell Transfusions; Platelet Transfusions; Plasma Transfusions; Stem Cell Infusions; Autologous Blood Transfusions

4) By Gene Therapies: Ex Vivo Gene Therapy; In Vivo Gene Therapy; Viral Vector Based Gene Therapy; Non Viral Vector Gene Therapy; Genome Editing Based Therapy

5) By Other Therapy Types: Cell Based Therapies; RNA Based Therapies; Protein Based Therapies; Combination Therapies; Experimental Therapies

What Trends Are Affecting The Growth Of The Monogenetic Disease Therapy Market?

Major companies within the monogenetic disease therapy market are concentrating on developing innovative gene therapies, such as Duchenne muscular dystrophy (DMD)–focused protocols, with the aim of slowing disease progression and improving long-term patient outcomes. These Duchenne muscular dystrophy–targeted protocols are structured clinical or therapeutic guidelines specifically designed to diagnose, monitor, and manage patients with Duchenne muscular dystrophy, emphasizing the deceleration of disease progression, enhancement of muscle function, and management of associated complications. For instance, in January 2026, Sarepta Therapeutics Inc, a US-based biopharmaceutical company, launched Elevidys for ambulatory patients aged four and older with DMD. This launch reported up to a 73% reduction in the rate of functional decline over three years when compared with an external control group, underscoring the significance of early intervention in altering the disease course and improving quality of life.

Which Key Players Are Active In The Monogenetic Disease Therapy Market?

Major companies operating in the monogenetic disease therapy market are Pfizer Inc., Sanofi S.A., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics Inc., Ptc therapeutics inc., Crispr therapeutics ag, CRISPR Therapeutics, Voyager Therapeutics Inc., Oxford Biomedica plc, REGENXBIO INC., Arcturus therapeutics holdings inc., Editas medicine Inc., American Gene Technologies, UniQure NV., MeiraGTx Limited, Prime medicine, Abeona therapeutics Inc., Blue Cross Blue Shield Association, Rocket pharmaceuticals Inc.

Access The Complete Monogenetic Disease Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/monogenetic-disease-therapy-market-report

Which Region Leads The Monogenetic Disease Therapy Market By Size?

North America was the largest region in the monogenetic disease therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monogenetic disease therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Monogenetic Disease Therapy Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model